These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28606093)

  • 1. Two steps forward, one step back: current harm reduction policy and politics in the United States.
    Nadelmann E; LaSalle L
    Harm Reduct J; 2017 Jun; 14(1):37. PubMed ID: 28606093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trump administration begins to confront the opioid crisis.
    Jaffe S
    Lancet; 2017 Nov; 390(10108):2133-2134. PubMed ID: 29143746
    [No Abstract]   [Full Text] [Related]  

  • 3. The value of harm reduction for injection drug use: A clinical and public health ethics analysis.
    Vearrier L
    Dis Mon; 2019 May; 65(5):119-141. PubMed ID: 30600096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic.
    Pitt AL; Humphreys K; Brandeau ML
    Am J Public Health; 2018 Oct; 108(10):1394-1400. PubMed ID: 30138057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From political controversy to a technical problem? Fifteen years of opioid substitution treatment in Finland.
    Selin J; Hakkarainen P; Partanen A; Tammi T; Tigerstedt C
    Int J Drug Policy; 2013 Nov; 24(6):e66-72. PubMed ID: 24095679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heroin-assisted treatment in Switzerland: a case study in policy change.
    Uchtenhagen A
    Addiction; 2010 Jan; 105(1):29-37. PubMed ID: 19922519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics.
    Fischer B; Oviedo-Joekes E; Blanken P; Haasen C; Rehm J; Schechter MT; Strang J; van den Brink W
    J Urban Health; 2007 Jul; 84(4):552-62. PubMed ID: 17562183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Today's fentanyl crisis: Prohibition's Iron Law, revisited.
    Beletsky L; Davis CS
    Int J Drug Policy; 2017 Aug; 46():156-159. PubMed ID: 28735773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public support for safe consumption sites and syringe services programs to combat the opioid epidemic.
    McGinty EE; Barry CL; Stone EM; Niederdeppe J; Kennedy-Hendricks A; Linden S; Sherman SG
    Prev Med; 2018 Jun; 111():73-77. PubMed ID: 29481827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Opiates, harm reduction and polysubstance abuse].
    Touzeau D; Courty P
    Presse Med; 2012 Dec; 41(12 Pt 1):1192-200. PubMed ID: 23122942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A different road to recovery.
    Jumnoodoo R; McMahon B; Hehir B; Humm C
    Nurs Stand; 2010 Jun 2-8; 24(39):26-7. PubMed ID: 20572550
    [No Abstract]   [Full Text] [Related]  

  • 12. Legal and ethical issues in heroin diagnosis, treatment, and research.
    Loue S; Ioan B
    J Leg Med; 2007; 28(2):193-221. PubMed ID: 17558793
    [No Abstract]   [Full Text] [Related]  

  • 13. Political challenges in randomized controlled trials of heroin-assisted treatment for severe heroin addiction: a Spanish experience.
    Trujols J; Iraurgi I
    Clin Trials; 2009 Dec; 6(6):658-9; author reply 660. PubMed ID: 20015836
    [No Abstract]   [Full Text] [Related]  

  • 14. Harm reduction in the USA: the research perspective and an archive to David Purchase.
    Des Jarlais DC
    Harm Reduct J; 2017 Jul; 14(1):51. PubMed ID: 28747189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harm Reduction Policy Support among Students at Two U.S. Universities.
    Andraka-Christou B; Nguyen T; Harris S; Atkins DN; Totaram R; Golan O; Koval A; Madeira J
    Subst Use Misuse; 2022; 57(8):1185-1195. PubMed ID: 35491710
    [No Abstract]   [Full Text] [Related]  

  • 16. Work and the journey to recovery: exploring the implications of welfare reform for methadone maintenance clients.
    Monaghan M; Wincup E
    Int J Drug Policy; 2013 Nov; 24(6):e81-6. PubMed ID: 24360401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could cannabis liberalisation lead to wider changes in drug policies and outcomes?
    Hughes B; Wiessing L; Des Jarlais D; Griffiths P
    Int J Drug Policy; 2018 Jan; 51():156-159. PubMed ID: 29229491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ever-changing narrative: Supervised injection site policy making in Ontario, Canada.
    Ziegler BR; Wray AJ; Luginaah I
    Int J Drug Policy; 2019 Dec; 74():98-111. PubMed ID: 31586776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syringe services programs: An examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S.
    Jones CM
    Int J Drug Policy; 2019 Aug; 70():22-32. PubMed ID: 31059965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility.
    Irwin A; Jozaghi E; Weir BW; Allen ST; Lindsay A; Sherman SG
    Harm Reduct J; 2017 May; 14(1):29. PubMed ID: 28532488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.